𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The distribution of nuchal translucency at 10–13 weeks of pregnancy

✍ Scribed by Katharina Schuchter; Nicholas Wald; Allan K. Hackshaw; Erich Hafner; Eva Liebhart


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
203 KB
Volume
18
Category
Article
ISSN
0197-3851

No coin nor oath required. For personal study only.

✦ Synopsis


There is a need for a simple method of expressing nuchal translucency measurement in early pregnancy that will allow for gestational age and be useful in screening for Down's syndrome. To achieve this objective, we conducted a prospective study of 561 women with singleton pregnancies that were not affected by Down's syndrome at 10-13 weeks of gestation. Nuchal translucency measurements and crown rump length measurements were determined. Nuchal translucency measurement increased by about 17 per cent per week. Expressing the result as a multiple of the median (MOM) nuchal translucency for a given crown rump length allowed for this increase with gestational age and yielded a distribution of values that was approximately Gaussian. About 96 per cent of values lay between 0•5 and 2•0 MOM. The variance and therefore the false-positive rate of nuchal translucency were significantly reduced by recording several measurements and using the average: for example, the false-positive rate reduced from 8•3 per cent to 5•0 per cent if the average of six measurements were used instead of one-a potential 40 per cent reduction in the false-positive rate if the test were used in screening. Estimating the distribution of nuchal translucency in MOM values will assist in specifying the statistical parameters to be used in prenatal screening for Down's syndrome and the use of repeated nuchal translucency measurements is expected to have a useful effect on reducing the screening false-positive rate at a given MOM cut-off level.


📜 SIMILAR VOLUMES


Increased nuchal translucency in trisomy
✍ Snijders, Rosalinde J.M.; Sebire, Neil J.; Nayar, Roshini; Souka, Athena; Nicola 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 14 KB 👁 1 views

In a multicenter screening study for trisomy 21 involving ultrasonographic measurement of fetal nuchal translucency thickness (NT) at 10-14 weeks of gestation, 100,311 singleton pregnancies with a live fetus were examined. There were 46 cases of trisomy 13, and in 33 (72%) of these, the NT was above

Results of routine fetal nuchal transluc
✍ E. Hafner; K. Schuchter; E. Liebhart; K. Philipp 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

The aim of this study was to determine the value of nuchal translucency (NT) measurement for the detection of aneuploidies and other malformations in a low-risk population. In total, 4233 women who booked in our hospital for delivery were examined between the tenth and 13th week of gestation. Of the

Detection of sex chromosome abnormalitie
✍ N. J. Sebire; R. J. M. Snijders; R. Brown; T. Southall; K. H. Nicolaides 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

At 10-14 weeks of gestation more than 80 per cent of fetuses affected by trisomy 21 can be detected by a screening programme based on a combination of maternal age and fetal nuchal translucency thickness (NT). The screen positive group in such a programme also identifies fetuses with sex chromosome

Screening for trisomy 13 by fetal nuchal
✍ Kevin Spencer; Charas Ong; Hara Skentou; Adolfo W. Liao; Kypros H. Nicolaides 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

In 42 cases of trisomy 13 at 10±14 weeks of gestation, compared with 947 controls, the median multiple of the median (MoM) of maternal serum free b-human chorionic gonadotrophin (b-hCG) and pregnancy associated plasma protein A (PAPP-A) was signi®cantly decreased (0.506 MoM and 0.248 MoM respectivel

First-trimester screening for Down syndr
✍ P. De Biasio; M. Siccardi; G. Volpe; L. Famularo; F. Santi; S. Canini 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

In a population of 1467 women attending the 'G. Gaslini' Institute for antenatal care, we evaluated first-trimester risk screening for Down syndrome using the 'combined test' based on ultrasound measurement of nuchal translucency (NT), maternal serum pregnancy-associated plasma protein A (PAPP-A) an